Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

Innovative approach using KITE-439 in targeting HPV-related malignancies

August 20, 2019 | City of Hope

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.

Natural killer cells: Breakthrough study examines cancer-fighting behavior

July 24, 2019 | Letisia Marquez

For the first time, City of Hope scientists have discovered that natural killer cells provide one reason why anti-PD-L1 antibodies might work when tumor cells do not express PD-L1.

Immunotherapy combo could tackle advanced cancers

June 18, 2019 | Zen Vuong

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.

Inspired by sci-fi, radiologist forges new frontiers in cancer diagnostics

June 4, 2019 | Maxine Nunes

Ammar Chaudhry, M.D., a radiologist with degrees in biology and physics and founder and director of City of Hope’s new Precision Imaging Lab, is currently working with some paradigm-shifting concepts that promise to transform the diagnosis and treatment of cancer patients.

Colorectal tumor biomarker may predict immunotherapy effectiveness

May 2, 2019 | Zen Vuong

The takeaway of foundational research by a City of Hope physician-scientist and his colleagues is that patients with metastatic colorectal cancer and a high tumor mutation score should consider immunotherapy as initial treatment.